Developer docs
API playgroundTry for free, no card

Search company profiles

Nima

Full company profile

uuid00022vj

Namestring
Nima
Legal namestring
NIMA Partners, Inc.
Websiteurl
nimanow.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

NIMA Partners, Inc. (operating as NIMA) is a privately held consumer health technology company that develops portable, antibody-based gluten detection devices. The company was originally founded in 2013 and launched its first pocket-sized gluten sensor; the original product was discontinued around 2020 due to ownership transitions and supply chain disruptions. In 2025, RA Capital Management made a transformational investment to rescue the company, and NIMA relaunched in January 2026 under new CEO Mike Glick with a next-generation sensor that detects gluten down to 10 parts per million with 99% accuracy — independently validated by Bia Diagnostics using AOAC reference methods and below the FDA's 20 ppm gluten-free threshold. The system consists of a reusable handheld sensor paired with single-use test capsules containing proprietary monoclonal antibodies that recognize gluten protein fragments from wheat (gliadin), barley (hordein), and rye (secalin), producing a YES/NO result in approximately three minutes. The NIMA Now mobile companion app logs results and manages device firmware.

NIMA sells primarily through direct-to-consumer e-commerce on nimanow.com (powered by Shopify), with hardware priced at $220 per sensor and a $330 Starter Pack that bundles the sensor with two boxes of six single-use capsules. Capsule refills ($72 per 6-pack, or $61.20 on a 15%-off subscription with auto-renewal and free shipping) form the recurring revenue engine. Distribution is limited to the United States, Canada, and Singapore. Secondary channels include B2B and employer wellness programs, clinician partnerships supported by a three-member clinical advisory board, a Champions ambassador program, and Shopify Collabs affiliate marketing. Truemed integration enables HSA/FSA reimbursement with a Letter of Medical Necessity for diagnosed users. The company has 11-50 employees, is headquartered in Boston (NIMA Partners, Inc., 200 Berkeley Street, 18th Floor), and operates as an FDA-registered consumer-use tool (explicitly not a medical or diagnostic device). Since the January 2026 relaunch, NIMA reports over 2,000 devices activated, 100,000+ meals tested, 90%+ customer satisfaction, and a 2026 Gold Stevie Award for product innovation.

Short descriptiontext

NIMA Partners is a privately held consumer health technology company that sells a portable, antibody-based gluten sensor ($220 device plus recurring single-use test capsules) direct-to-consumer, serving individuals with celiac disease and gluten sensitivity who need real-time food verification, primarily in the US, Canada, and Singapore.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
portable gluten sensor, food allergy testing, celiac disease devices, lateral flow immunoassay, consumer health hardware
Industry2 codes
PRIMARYHLAHAHAD
Smart Insulin Pens & Connected Pen Caps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
Product category
Consumer Health Devices / Food Safety Testing
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Gluten Sensor Device (Hardware)
TypeHardware Sales
Description

One-time sale of the NIMA Gluten Sensor device (the Shield) at $220 per unit. The Starter Pack bundles the sensor with 12 capsules for $330. Sensors include a 1-year limited warranty.

nimanow.com
2Single-Use Test Capsules
TypeSubscription Recurring
Description

Recurring consumable revenue from 6-pack capsule purchases at $72 per box, or $61.20 per box on subscription (15% discount). Capsule subscription model drives recurring revenue with auto-renewal and free shipping.

nimanow.com
3HSA/FSA Reimbursement Facilitation
TypeAffiliate Referral
Description

Through Truemed partnership, customers can use HSA/FSA funds and obtain a Letter of Medical Necessity, facilitating purchase for individuals with diagnosed celiac or gluten sensitivity, expanding addressable market.

nimanow.com
Marketing channels10 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
Pricing details6 tiers
1NIMA Starter Pack — $330 (sensor + 12 capsules)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Starter Pack at $330 includes: 1 NIMA Sensor, 2 boxes of NIMA Capsules (6 per box), USB-C charging cable, and travel bag. One-time purchase with 30-day satisfaction guarantee and 1-year limited warranty.

nimanow.com
2NIMA Gluten Sensor (standalone) — $220
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Next-generation sensor with enhanced LED illumination, USB-C charging, 30-40 cycles per charge, and app integration. Standalone purchase. 30-day satisfaction guarantee and 1-year limited warranty.

nimanow.com
3NIMA Gluten Capsules 6-pack — $72 (one-time) or $61.20 (subscription)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Single-use capsules: $72 per 6-pack one-time; $61.20 per 6-pack with Subscribe & Save (15% off). Subscription includes auto-renewal, free shipping, and VIP exclusive perks. Capsules stable for ~12 months from manufacture when stored properly.

nimanow.com
4NIMA Capsule Subscription — 15% off + free shipping
ModelSubscriptionBilling cadenceMonthly
Notes

Subscribe & Save: 15% off all recurring capsule orders with automatic deliveries. Flexible delivery frequencies (3 weeks, 1 month, 2 months, 3 months). Auto-renews with ability to skip, adjust, or cancel anytime. Free shipping on all subscription orders.

nimanow.com
5NIMA Travel Case — $19.99
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Protective travel case for the sensor and capsules, sold as a one-time purchase.

nimanow.com
6NIMA Gift Card — from $25
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Digital gift cards available in denominations starting at $25, for flexible gifting of NIMA products.

nimanow.com
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1NIMA Now
Description

Mobile application for NIMA gluten sensor that logs test results, provides step-by-step testing guidance, and manages the device.

nimanow.com
+1 more record
Core offering1 text field

NIMA sells a portable, reusable handheld gluten-detection sensor ("the Shield") priced at $220, paired with single-use proprietary test capsules (6-pack at $72 one-time or $61.20 on subscription). A Starter Pack bundling the sensor with 12 capsules is sold for $330. The system detects gluten from wheat, barley, and rye down to 10 ppm with 99% validated accuracy in approximately 3 minutes per test, integrating with the NIMA Now mobile app for automatic result logging and step-by-step guidance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 99% accuracy at 10 ppm, independently validated by Bia Diagnostics using AOAC reference methods — below the FDA gluten-free threshold of 20 ppm
+6 more records
Product overview1 text field

NIMA is a consumer-use gluten detection system consisting of a portable handheld sensor device and single-use test capsules. The core offering is the NIMA™ Gluten Sensor, a reusable device that pairs with NIMA™ Gluten Capsules to detect gluten in food samples down to 10 ppm. The NIMA™ Starter Pack bundles the sensor with two boxes of capsules for new users. Accessories include the NIMA™ Travel Case for portability and NIMA™ Gift Cards for gifting. The system uses lateral-flow antibody-based immunoassay technology with monoclonal antibodies recognizing gluten proteins from wheat (gliadin), barley (hordein), and rye (secalin). All products integrate with the NIMA Now mobile app for automatic result logging and testing guidance.

Product and service5 records
1NIMA Gluten Sensor (the Shield)
CategoryCore Product — Gluten Detection Hardware
Description

A portable, reusable handheld gluten-detection device priced at $220. Analyzes a pea-sized food sample via single-use capsules using lateral-flow antibody-based immunoassay technology, delivering a YES/NO gluten result in approximately 3 minutes at 10 ppm sensitivity with 99% validated accuracy. Designed for individuals with celiac disease and gluten sensitivity who need real-time food safety verification when dining out, traveling, or attending social events.

2NIMA Gluten Capsules (6-pack)
CategoryCore Product — Single-Use Test Consumables
Description

Single-use test capsules priced at $72 per 6-pack (one-time) or $61.20 per 6-pack on subscription (15% off). Each capsule contains proprietary reagents and a custom extraction buffer; twisting the lid automatically mixes the food sample for analysis. Capsules are stable for approximately 12 months from manufacture and are the recurring-consumable revenue driver behind the hardware razor.

3NIMA Starter Pack
CategoryCore Product — Hardware + Consumables Bundle
Description

Bundled package priced at $330 containing one NIMA Sensor device, two boxes of NIMA Capsules (6 per box), a USB-C charging cable, and a travel bag. Designed as the entry point for new users, including a 30-day satisfaction guarantee and a 1-year limited warranty.

4NIMA Travel Case
CategoryAccessory — Portability
Description

Protective travel case priced at $19.99 that keeps the NIMA sensor and capsules organized while traveling. Marketed as an accessory that supports portability and convenience for users who need gluten detection on the go.

5NIMA Gift Card
CategoryAccessory — Gifting
Description

Digital gift card option for purchasing NIMA products, available in denominations starting at $25. Provides a flexible way for the celiac and gluten-sensitive community to gift NIMA hardware, capsules, or accessories.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeTechnology or Integration
Description

Bia Diagnostics independently validated NIMA's gluten detection technology in October 2025, measuring 99% accuracy at 10 ppm using AOAC reference methods. Bia Diagnostics verification covers wheat, rye, and barley detection. This third-party validation is prominently featured on NIMA's product pages and marketing materials as a key credibility marker.

Strategic tierCoreTypeOthers
Description

Truemed is a payment platform partner that enables NIMA customers to use HSA/FSA funds for purchases. Truemed coordinates independent practitioner evaluation and issues a Letter of Medical Necessity (LMN) for eligible customers, making NIMA products reimbursable through tax-advantaged health accounts. This partnership expands NIMA's addressable market by enabling purchase through HSA/FSA accounts.

3Kate Bourke, RD
Strategic tierMinorTypeOthers
Description

Registered dietitian and key opinion leader on NIMA's advisory network. Focuses on shaping patient-facing programs and messaging, especially for newly diagnosed celiac patients. Dr. Bourke is part of NIMA's network of trusted experts supporting smarter healthcare decisions.

nimanow.com
4Salvo Alesci, MD, PhD
Strategic tierMinorTypeOthers
Description

Physician-scientist and key opinion leader on NIMA's advisory network. Focuses on identifying highest-leverage environments to generate credible real-world evidence for gluten detection and celiac management.

nimanow.com
Strategic tierMinorTypeOthers
Description

Gastroenterologist and key opinion leader on NIMA's advisory network. Focuses on advising on physician adoption pathways across screening, surveillance, and monitoring for celiac patients.

Strategic tierMinorTypeGTM or Marketing Partner
Description

NIMA uses Shopify Collabs to recruit and manage affiliate partners — creators, bloggers, and advocates in the gluten-free community — who promote NIMA in exchange for referral commissions.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Bia Diagnostics is the third-party lab that validated NIMA's 99% accuracy claim and serves as a quality reference point in the company's regulatory and marketing story — adjacent ecosystem participant rather than a competitor.

2Cue Health
TypeDirect peer
Description

Cue Health makes a consumer-facing, portable molecular diagnostic device with single-use test cartridges and a companion app — the same hardware-plus-consumables-plus-app architecture NIMA uses, but for respiratory and other molecular targets.

TypeDirect peer
Description

Levels sells a direct-to-consumer continuous glucose monitor paired with an app for personalized metabolic insights, exemplifying the same D2C consumer-health-device + subscription consumables + community model NIMA employs.

TypeBroad incumbent
Description

Oura is a larger D2C consumer health wearable with a strong subscription and app ecosystem, demonstrating the scale the consumer-health-device + membership model can reach — a useful comparable for NIMA's long-term ambition.

TypeDirect peer
Description

Everlywell sells direct-to-consumer at-home health test kits (food sensitivity, celiac screening, etc.) with digital results, making it the closest comparable for at-home consumer diagnostics sold via e-commerce.

6Abbott (FreeStyle Libre)
TypeBroad incumbent
Description

Abbott's FreeStyle Libre is the dominant consumer-use continuous glucose monitor with disposable sensors and an app — a blueprint for how a single-use consumable + reader model can scale to billions in revenue if NIMA's allergen-detection franchise expands.

TypeEmerging player
Description

Viome sells direct-to-consumer gut microbiome and food-sensitivity test kits with personalized dietary recommendations, competing for the same health-conscious consumer wallet share that NIMA targets.

TypeEmerging player
Description

Tasso develops at-home blood collection and diagnostic devices that pair a reusable device with single-use sample cartridges, closely mirroring NIMA's reusable-sensor-plus-single-use-capsule architecture.

96SensorLabs (now Nimble Science)
TypeEmerging player
Description

6SensorLabs was the original sister company to the 2013-vintage NIMA, developing a portable peanut allergen sensor using analogous antibody-based detection — the closest historical analog and former direct peer in the consumer allergen-sensor category.

TypeBroad incumbent
Description

Eurofins is a global food testing laboratory that provides certified gluten and allergen analysis to food manufacturers — a broad incumbent that defines the centralized lab alternative to NIMA's at-home testing model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nima

Consumer Health Devices / Food Safety Testingnimanow.com

NIMA Partners is a privately held consumer health technology company that sells a portable, antibody-based gluten sensor ($220 device plus recurring single-use test capsules) direct-to-consumer, serving individuals with celiac disease and gluten sensitivity who need real-time food verification, primarily in the US, Canada, and Singapore.

What Nima does

NIMA Partners, Inc. (operating as NIMA) is a privately held consumer health technology company that develops portable, antibody-based gluten detection devices. The company was originally founded in 2013 and launched its first pocket-sized gluten sensor; the original product was discontinued around 2020 due to ownership transitions and supply chain disruptions. In 2025, RA Capital Management made a transformational investment to rescue the company, and NIMA relaunched in January 2026 under new CEO Mike Glick with a next-generation sensor that detects gluten down to 10 parts per million with 99% accuracy — independently validated by Bia Diagnostics using AOAC reference methods and below the FDA's 20 ppm gluten-free threshold. The system consists of a reusable handheld sensor paired with single-use test capsules containing proprietary monoclonal antibodies that recognize gluten protein fragments from wheat (gliadin), barley (hordein), and rye (secalin), producing a YES/NO result in approximately three minutes. The NIMA Now mobile companion app logs results and manages device firmware.

NIMA sells primarily through direct-to-consumer e-commerce on nimanow.com (powered by Shopify), with hardware priced at $220 per sensor and a $330 Starter Pack that bundles the sensor with two boxes of six single-use capsules. Capsule refills ($72 per 6-pack, or $61.20 on a 15%-off subscription with auto-renewal and free shipping) form the recurring revenue engine. Distribution is limited to the United States, Canada, and Singapore. Secondary channels include B2B and employer wellness programs, clinician partnerships supported by a three-member clinical advisory board, a Champions ambassador program, and Shopify Collabs affiliate marketing. Truemed integration enables HSA/FSA reimbursement with a Letter of Medical Necessity for diagnosed users. The company has 11-50 employees, is headquartered in Boston (NIMA Partners, Inc., 200 Berkeley Street, 18th Floor), and operates as an FDA-registered consumer-use tool (explicitly not a medical or diagnostic device). Since the January 2026 relaunch, NIMA reports over 2,000 devices activated, 100,000+ meals tested, 90%+ customer satisfaction, and a 2026 Gold Stevie Award for product innovation.

Nima firmographics

Firmographics
Name
Nima
Legal name
NIMA Partners, Inc.
Website
https://nimanow.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
NIMA Partners is a privately held consumer health technology company that sells a portable, antibody-based gluten sensor ($220 device plus recurring single-use test capsules) direct-to-consumer, serving individuals with celiac disease and gluten sensitivity who need real-time food verification, primarily in the US, Canada, and Singapore.
Ownership category
akta.pro rank

Nima industry classification

Industry
Product category
Consumer Health Devices / Food Safety Testing
akta.pro industry
PRIMARYHLAHAHAD
Smart Insulin Pens & Connected Pen Caps
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAOAK
Home-Use & OTC Rapid Self-Tests (Consumer POCT kits)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics

Keywords

  • Portable gluten sensor
  • Food allergy testing
  • Celiac disease devices
  • Lateral flow immunoassay
  • Consumer health hardware

Where Nima is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nima business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Gluten Sensor Device (Hardware): One-time sale of the NIMA Gluten Sensor device (the Shield) at $220 per unit. The Starter Pack bundles the sensor with 12 capsules for $330. Sensors include a 1-year limited warranty.
  2. Single-Use Test Capsules: Recurring consumable revenue from 6-pack capsule purchases at $72 per box, or $61.20 per box on subscription (15% discount). Capsule subscription model drives recurring revenue with auto-renewal and free shipping.
  3. HSA/FSA Reimbursement Facilitation: Through Truemed partnership, customers can use HSA/FSA funds and obtain a Letter of Medical Necessity, facilitating purchase for individuals with diagnosed celiac or gluten sensitivity, expanding addressable market.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goNIMA Starter Pack — $330 (sensor + 12 capsules)
One time/ perpetual licensePay-as-you-goNIMA Gluten Sensor (standalone) — $220
Unit PricingPay-as-you-goNIMA Gluten Capsules 6-pack — $72 (one-time) or $61.20 (subscription)
SubscriptionMonthlyNIMA Capsule Subscription — 15% off + free shipping
One time/ perpetual licensePay-as-you-goNIMA Travel Case — $19.99
One time/ perpetual licensePay-as-you-goNIMA Gift Card — from $25

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Nima product offering

Product offering

Core offering

NIMA sells a portable, reusable handheld gluten-detection sensor ("the Shield") priced at $220, paired with single-use proprietary test capsules (6-pack at $72 one-time or $61.20 on subscription). A Starter Pack bundling the sensor with 12 capsules is sold for $330. The system detects gluten from wheat, barley, and rye down to 10 ppm with 99% validated accuracy in approximately 3 minutes per test, integrating with the NIMA Now mobile app for automatic result logging and step-by-step guidance.

Product overview

NIMA is a consumer-use gluten detection system consisting of a portable handheld sensor device and single-use test capsules. The core offering is the NIMA™ Gluten Sensor, a reusable device that pairs with NIMA™ Gluten Capsules to detect gluten in food samples down to 10 ppm. The NIMA™ Starter Pack bundles the sensor with two boxes of capsules for new users. Accessories include the NIMA™ Travel Case for portability and NIMA™ Gift Cards for gifting. The system uses lateral-flow antibody-based immunoassay technology with monoclonal antibodies recognizing gluten proteins from wheat (gliadin), barley (hordein), and rye (secalin). All products integrate with the NIMA Now mobile app for automatic result logging and testing guidance.

Differentiator

Problem solved

Functional benefit

Brands

  • NIMA Now: Mobile application for NIMA gluten sensor that logs test results, provides step-by-step testing guidance, and manages the device.
  • The Shield

Products and services

  • NIMA Gluten Sensor (the Shield) A portable, reusable handheld gluten-detection device priced at $220. Analyzes a pea-sized food sample via single-use capsules using lateral-flow antibody-based immunoassay technology, delivering a YES/NO gluten result in approximately 3 minutes at 10 ppm sensitivity with 99% validated accuracy. Designed for individuals with celiac disease and gluten sensitivity who need real-time food safety verification when dining out, traveling, or attending social events.
  • NIMA Gluten Capsules (6-pack) Single-use test capsules priced at $72 per 6-pack (one-time) or $61.20 per 6-pack on subscription (15% off). Each capsule contains proprietary reagents and a custom extraction buffer; twisting the lid automatically mixes the food sample for analysis. Capsules are stable for approximately 12 months from manufacture and are the recurring-consumable revenue driver behind the hardware razor.
  • NIMA Starter Pack Bundled package priced at $330 containing one NIMA Sensor device, two boxes of NIMA Capsules (6 per box), a USB-C charging cable, and a travel bag. Designed as the entry point for new users, including a 30-day satisfaction guarantee and a 1-year limited warranty.
  • NIMA Travel Case Protective travel case priced at $19.99 that keeps the NIMA sensor and capsules organized while traveling. Marketed as an accessory that supports portability and convenience for users who need gluten detection on the go.
  • NIMA Gift Card Digital gift card option for purchasing NIMA products, available in denominations starting at $25. Provides a flexible way for the celiac and gluten-sensitive community to gift NIMA hardware, capsules, or accessories.

Quantifiable outcome

  • 99% accuracy at 10 ppm, independently validated by Bia Diagnostics using AOAC reference methods — below the FDA gluten-free threshold of 20 ppm
  • +6 more outcomes

Companies that use Nima

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Nima technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability2 records

Feature6 records

Nima partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Bia DiagnosticscoreTechnology or IntegrationBia Diagnostics independently validated NIMA's gluten detection technology in October 2025, measuring 99% accuracy at 10 ppm using AOAC reference methods. Bia Diagnostics verification covers wheat, rye, and barley detection. This third-party validation is prominently featured on NIMA's product pages and marketing materials as a key credibility marker.
  • TruemedcoreOthersTruemed is a payment platform partner that enables NIMA customers to use HSA/FSA funds for purchases. Truemed coordinates independent practitioner evaluation and issues a Letter of Medical Necessity (LMN) for eligible customers, making NIMA products reimbursable through tax-advantaged health accounts. This partnership expands NIMA's addressable market by enabling purchase through HSA/FSA accounts.
  • Kate Bourke, RDminorOthersRegistered dietitian and key opinion leader on NIMA's advisory network. Focuses on shaping patient-facing programs and messaging, especially for newly diagnosed celiac patients. Dr. Bourke is part of NIMA's network of trusted experts supporting smarter healthcare decisions.
  • Salvo Alesci, MD, PhDminorOthersPhysician-scientist and key opinion leader on NIMA's advisory network. Focuses on identifying highest-leverage environments to generate credible real-world evidence for gluten detection and celiac management.
  • Jignesh Shah, MDminorOthersGastroenterologist and key opinion leader on NIMA's advisory network. Focuses on advising on physician adoption pathways across screening, surveillance, and monitoring for celiac patients.
  • Shopify CollabsminorGTM or Marketing PartnerNIMA uses Shopify Collabs to recruit and manage affiliate partners — creators, bloggers, and advocates in the gluten-free community — who promote NIMA in exchange for referral commissions.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Nima competitors and assessment

Company assessment

Others

  • Bia Diagnostics: Bia Diagnostics is the third-party lab that validated NIMA's 99% accuracy claim and serves as a quality reference point in the company's regulatory and marketing story — adjacent ecosystem participant rather than a competitor.

Direct peers

  • Cue Health: Cue Health makes a consumer-facing, portable molecular diagnostic device with single-use test cartridges and a companion app — the same hardware-plus-consumables-plus-app architecture NIMA uses, but for respiratory and other molecular targets.
  • Levels Health: Levels sells a direct-to-consumer continuous glucose monitor paired with an app for personalized metabolic insights, exemplifying the same D2C consumer-health-device + subscription consumables + community model NIMA employs.
  • Everlywell: Everlywell sells direct-to-consumer at-home health test kits (food sensitivity, celiac screening, etc.) with digital results, making it the closest comparable for at-home consumer diagnostics sold via e-commerce.

Broad incumbents

  • Oura: Oura is a larger D2C consumer health wearable with a strong subscription and app ecosystem, demonstrating the scale the consumer-health-device + membership model can reach — a useful comparable for NIMA's long-term ambition.
  • Abbott (FreeStyle Libre): Abbott's FreeStyle Libre is the dominant consumer-use continuous glucose monitor with disposable sensors and an app — a blueprint for how a single-use consumable + reader model can scale to billions in revenue if NIMA's allergen-detection franchise expands.
  • Eurofins Scientific: Eurofins is a global food testing laboratory that provides certified gluten and allergen analysis to food manufacturers — a broad incumbent that defines the centralized lab alternative to NIMA's at-home testing model.

Emerging players

  • Viome: Viome sells direct-to-consumer gut microbiome and food-sensitivity test kits with personalized dietary recommendations, competing for the same health-conscious consumer wallet share that NIMA targets.
  • Tasso: Tasso develops at-home blood collection and diagnostic devices that pair a reusable device with single-use sample cartridges, closely mirroring NIMA's reusable-sensor-plus-single-use-capsule architecture.
  • 6SensorLabs (now Nimble Science): 6SensorLabs was the original sister company to the 2013-vintage NIMA, developing a portable peanut allergen sensor using analogous antibody-based detection — the closest historical analog and former direct peer in the consumer allergen-sensor category.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Nima social profiles

Digital presence

Nima compliance and trust

Trust signal

Compliance1 record

Nima financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nima leadership team

Management profile

Number of profiles

Profiles6 records

Nima funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nima M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nima

What does Nima do?

NIMA sells a portable, reusable handheld gluten-detection sensor ("the Shield") priced at $220, paired with single-use proprietary test capsules (6-pack at $72 one-time or $61.20 on subscription). A Starter Pack bundling the sensor with 12 capsules is sold for $330. The system detects gluten from wheat, barley, and rye down to 10 ppm with 99% validated accuracy in approximately 3 minutes per test, integrating with the NIMA Now mobile app for automatic result logging and step-by-step guidance.

Is Nima a public or private company?

Nima is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nima founded?

Nima was founded in 2015. It employs 11 to 50 people.

Where is Nima based?

Nima is headquartered in San Francisco, United States, in the North America region.

How does Nima make money?

Three revenue lines are on record. Gluten Sensor Device (Hardware) is the primary driver. The others are single-Use Test Capsules and HSA/FSA Reimbursement Facilitation.

Who are Nima's main competitors?

Bia Diagnostics is listed as an others. Direct peers are Cue Health, Levels Health and Everlywell. Broad incumbents are Oura, Abbott (FreeStyle Libre) and Eurofins Scientific. Emerging players are Viome, Tasso and 6SensorLabs (now Nimble Science).

Does Nima have an API?

No public API is recorded for Nima.

What industry is Nima in?

Nima's product category is Consumer Health Devices / Food Safety Testing. Its primary akta.pro industry code is HLAHAHAD, Smart Insulin Pens & Connected Pen Caps, with a secondary code of HLAHAOAK, Home-Use & OTC Rapid Self-Tests (Consumer POCT kits).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireNIMA and RA Capital Launch First-of-Its-Kind Workplace Pilot to Support Employees with Celiac DiseaseRA Capital Management announced a workplace pilot with NIMA Partners, making it the first employer to fully subsidize NIMA's portable gluten sensors. Starting July 1, eligible employees and family members with celiac disease or medically necessary gluten-free diets will access the devices at no cost. The pilot builds on RA Capital's 2025 investment in NIMA.GlobeNewswireNIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product InnovationNIMA Partners, Inc. won a Gold Stevie® Award for Achievement in Product Innovation at the 2026 American Business Awards® for its next-generation portable gluten sensor, which was relaunched in January 2026. The sensor detects gluten down to 10 parts per million with 99% accuracy validated by Bia Diagnostics using AOAC reference methods. Since the relaunch, over 2,000 devices have been activated, supporting more than 100,000 meals and achieving 90%+ customer satisfaction among users with celiac disease and gluten intolerance.GlobeNewswireNIMA’s Next-Gen Portable Gluten Sensor Wins Gold Stevie® Award for Achievement in Product InnovationNIMA Partners, Inc. won a Gold Stevie® Award for Achievement in Product Innovation at the 2026 American Business Awards® for its next-generation portable gluten sensor, which was relaunched in January 2026. The device detects gluten down to 10 parts per million across wheat, barley, and rye, achieving 99% accuracy in independent validation by Bia Diagnostics using AOAC reference methods. Since the relaunch, over 2,000 devices have been activated, supporting more than 100,000 meals with 90%+ customer satisfaction.American City Business JournalsRA Capital resurrects Nima's portable gluten-testing deviceRA Capital has invested in Nima, a gluten-detection startup, after supply chain problems nearly ended the company whose portable testing device is used by celiac patients for safe dining. The Boston-based startup was rescued by the investor whose family personally relies on the technology due to his son's celiac disease.The Epoch TimesBhutanese Conjoined Twins Return Home After Surgery in AustraliaConjoined twins Dawa and Nima, born in Bhutan in 2017, returned home after receiving surgery in Australia. The six-hour procedure involved about 25 medical staff, and the twins are Bhutan's first conjoined twins. They are expected to recover and continue developing.PrwebScientifically Proven: The Nima Sensor Can Improve the Quality of Life for Those with Celiac DiseaseNima announced a study published in Clinical Gastroenterology and Hematology showing its Gluten Sensor lowered depression among adult Celiac patients. The study of 30 participants found over 90% agreed the device was easy to use and helpful. Nima plans to share additional studies as they are published.TechCrunchNima launches food sensor to detect peanutsNima, a food sensor company and TechCrunch Battlefield alumnus, launched its second product on September 6: a peanut sensor capable of detecting 10 parts per million of peanut protein in under five minutes. The device connects to a smartphone app via Bluetooth, retails at $229 (or $289 with 12 test capsules), and claims a 97.6 percent accuracy rate based on internal testing. The peanut sensor follows Nima's first product for gluten detection, with plans to expand testing capabilities to additional nuts in the future.TechAcuteMake More Informed Dining Decisions with the Nima Peanut SensorNima Labs introduced the Peanut Sensor, a portable device that tests food for peanut protein in minutes. It detects 10 parts per million, the lowest adverse effect level from clinical studies. The Starter Kit costs $289, with capsules and a premium membership available.TechCrunchNima announces a $289 portable peanut allergy testerNima announced a portable peanut allergy tester, Peanut, that detects peanuts or gluten to 20 parts per million at 99 percent accuracy. The device ships with a 12-pack of test capsules for $229, with pre-orders before March 8, 2018, offering a $60 discount. The company also announced an improved gluten tester and a subscription plan.TechCrunchInciting a new futureSwati Mylavarapu and Matt Rogers, the Silicon Valley power couple, have launched Incite, a new investment platform with three distinct vehicles: a venture fund (Incite Ventures), a private foundation (Incite Labs), and a political arm (Incite Politics). Unlike traditional venture firms, Incite is funded entirely from the founders' personal funds with no limited partners, allowing them to offer patient capital and support startups where returns may take up to 20 years. The pair, who previously co-founded Nest Labs (sold to Google for $3.2 billion in 2014), have already funded 24 projects including Wright Electric Airplanes and food allergen detector maker Nima.